Review Decision – June 2016
Review of NICE guidance TA284; Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced and/or metastatic ovarian cancer, and TA285; Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Decision to move the existing guidance to the static list – June 2016
The Institute was proposing that both TA284 and TA285 should be moved to the static list.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, both TA284 and TA285 will be moved to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: